Healthcare Jan 30, 2023 10:44 AM (GMT+8) · EqualOcean
Levostar (Chinese: 左旋星生物) has raised the second financing round since its founding in 2022, which was led by Matrix Partner (Chinese: 经纬创投). Proceeds will be used to expand the GMP-level production and upgrade safety testing and evaluation platform for CGT products. Levostar is a developer and producer of cell gene therapy products intended to provide breakthrough technologies and full-coverage solutions for the CGT industry. The company's products include its clinical testing services for cell therapy platforms, viral vector platforms, mRNA vaccines and therapeutic platforms, and GMP-level production processes and product quality control methods for plasmids and mRNAs, enabling the biotechnological industry to accelerate the process of gene cell therapy and mRNA drug research and developm

Source: